Dr Reddy's Laboratories

雷迪博士实验室

on Thursday said it has joined hands with global biotech firm

周四表示，已与全球生物技术公司携手

Alvotech

阿尔沃科技

to co-develop and commercialise a biosimilar

共同开发并商业化一种生物类似药

product

产品

for treating multiple types of cancer.

用于治疗多种类型的癌症。

The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a

总部位于海得拉巴的制药巨头已达成合作和许可协议，以共同开发、制造和商业化一种产品。

biosimilar

生物仿制药

candidate to

候选人

Keytruda

Keytruda

(pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement.

Dr Reddy's Laboratories在一份声明中表示，（pembrolizumab）用于全球市场。

Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types.

Keytruda（pembrolizumab）被指示用于治疗多种癌症类型。

In 2024, worldwide sales of Keytruda were USD 29.5 billion.

2024年，Keytruda的全球销售额为295亿美元。

The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted.

公司指出，此次合作结合了Dr Reddy's和Alvotech在生物类似药领域的成熟能力，从而加快了开发进程，并扩大了这款生物类似药候选产品在全球的覆盖范围。

Live Events

现场活动

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated.

根据协议条款，各方将共同负责开发生物仿制药候选药物并分担成本和责任，声明中指出。

Subject to certain exceptions, each party will have the right to commercialize the product globally, it added.

它补充说，除某些例外情况外，各方将有权在全球范围内将该产品商业化。

'Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in

“肿瘤学一直是我们关注的首要治疗领域，此次合作将进一步提升我们在肿瘤学方面的能力，因为派姆单抗目前是最关键的疗法之一。

immuno-oncology

免疫肿瘤学

,' Dr Reddy's CEO Erez Israeli said.

“，Dr Reddy's首席执行官Erez Israeli表示。

Alvotech chairman and CEO

阿尔沃科技董事长兼首席执行官

Robert Wessman

罗伯特·韦斯曼

said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets.

表示该协议展示了 Alvotech 利用其专注的生物仿制药研发和生产平台的能力，通过开拓不断增长的全球市场来加速其产品线的扩展。

'It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' he added.

“它还使我们能够提高全球患者获得具有成本效益的关键生物药物的机会，”他补充道。

Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on

瑞迪博士实验室的股票每股交易价格上涨了3.49％，达到1,295.80卢比。

BSE

牛市

.

。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)